Roivant Sciences Ltd.(ROIV) Stock Research - Grey Stern Research
Loading...

Roivant Sciences Ltd. (ROIV) Stock Analysis

$11.23 (-1.58%)

ROIV Financial Performance


Use the table below to view Roivant Sciences Ltd.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $11.41 -
52 Week Low $8.25 -
52 Week High $13.24 -
Market Cap $9.2 Billion 3/15
Gross Margin 90% 6/15
Profit Margin 100% 1/15
EBITDA margin -605% 8/15
Q3 - 2024 Revenue $37.1 Million 6/15
Q3 - 2024 Earnings $5.1 Billion 1/15
Q3 - 2024 Free Cash Flow -$210.8 Billion 14/15
Trailing 4 Quarters Revenue $123.2 Million 5/15
Trailing 4 Quarters Earnings $4.3 Billion 1/15
Quarterly Earnings Growth 1424% 1/15
Annual Earnings Growth 425% 1/15
Quarterly Revenue Growth 118% 5/15
Annual Revenue Growth 126% 3/15
Cash On Hand $6.7 Billion 1/15
Short Term Debt $56.2 Million 4/15
Long Term Debt $450.4 Million 2/15

Roivant Sciences Ltd. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Roivant Sciences Ltd.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 2.13 1/15
PS 74.61 9/15
PB 1.40 12/15
PC 1.38 14/15
Liabilities to Equity 0.12 6/15
ROA 0.59 1/15
ROE 0.71 2/15
Current Ratio 10.04 7/15
Quick Ratio 9.16 7/15
Long Term Debt to Equity 0.07 3/15
Debt to Equity 0.08 5/15
Burn Rate -1.32 13/15
Cash to Cap 0.73 2/15
CCR -0.04 13/15
EV to EBITDA -13.48 6/15
EV to Revenue 24.59 10/15

Company Details

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

CEO:

Website: https://roivant.com

Address: 11-12 St. James’s Square London,

Exchange: NASDAQ Global Market

Industry: Biotechnology

Roivant Sciences Ltd. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Roivant Sciences Ltd.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
BeiGene, Ltd. BGNE $18.5 Billion
Blueprint Medicines Corporation BPMC $6.6 Billion
Syndax Pharmaceuticals, Inc. SNDX $1.7 Billion
Apellis Pharmaceuticals, Inc. APLS $5.0 Billion
Krystal Biotech, Inc. KRYS $4.7 Billion
Ascendis Pharma A/S ASND $6.9 Billion
Revolution Medicines, Inc. RVMD $6.5 Billion
Phathom Pharmaceuticals, Inc. PHAT $617.0 Million
Lyra Therapeutics, Inc. LYRA $23.3 Million
Pliant Therapeutics, Inc. PLRX $921.2 Million
Inozyme Pharma, Inc. INZY $284.5 Million
Prometheus Biosciences, Inc. RXDX $9.6 Billion
Viridian Therapeutics, Inc. VRDN $858.4 Million
Day One Biopharmaceuticals, Inc. DAWN $1.4 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ROIV Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 37.1 Million $5.1 Billion
Q2 2024 $ 37.1 Million -$304.3 Million
Q1 2024 $ 21.6 Million -$291.8 Million
Q4 2023 $ 27.4 Million -$175.4 Million
Q3 2023 $ 17.1 Million -$384.9 Million
Q2 2023 $ 12.5 Million -$315.9 Million
Q1 2023 $ 4.3 Million -$353.8 Million
Q4 2022 $ 9.2 Million -$291.3 Million

View All

ROIV Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $6.7 Billion $7.3 Billion $506.6 Million $6.6 Billion
Q2 2024 $1.4 Billion $2.1 Billion $498.0 Million $1.3 Billion
Q1 2024 $1.4 Billion $2.1 Billion $492.6 Million $910.7 Million
Q4 2023 $1.7 Billion $2.4 Billion $481.4 Million $1.6 Billion
Q3 2023 $1.5 Billion $2.2 Billion $479.6 Million $1.4 Billion
Q2 2023 $1.6 Billion $2.2 Billion $477.3 Million $1.2 Billion
Q1 2023 $1.9 Billion $2.6 Billion $489.3 Million $1.4 Billion
Q4 2022 $2.1 Billion $2.6 Billion $283.9 Million $2.0 Billion

View All

ROIV Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$210.8 Million -$355,000 $5.3 Billion
Q2 2024 -$196.7 Million -$275,000 -$26.5 Million
Q1 2024 -$250.3 Million -$403,000 -$242.5 Million
Q4 2023 -$180.7 Million -$1.6 Million $151.1 Million
Q3 2023 -$223.1 Million -$508,000 -$71.6 Million
Q2 2023 -$192.7 Million -$3.1 Million -$343.8 Million
Q1 2023 -$259.5 Million -$7.5 Million -$117.6 Million
Q4 2022 -$153.7 Million -$6.3 Million -$152.1 Million

View All